Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1606 participants.

Also called NCT04707469

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,606 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04707469
  • EudraCT 2020-000299-39
Other papers using this trial's data
  • Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial Lancet (London, England), 2023-08-26 DOI, PubMed 37385279

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Bulgaria, Canada, Croatia, Czechia, Estonia, Germany, Hungary, India, Poland, Puerto Rico, Slovakia, Slovenia, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04707469. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-15 (actual); primary completion 2023-03-07 (actual). Results posted on 2024-04-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes
Acronym
PIONEER PLUS
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Oral semaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04707469
Content hash
fd64cb01802e846625121017e511344c5e7fffbee2657a547e1b5f5dea21f9a1